Sarepta Therapeutics Inc.
NASDAQ · SRPT·Cambridge, MA·Large-cap·Approved
Gene therapy and RNA leader in Duchenne muscular dystrophy with Elevidys (delandistrogene moxeparvovec) and exon-skipping RNA franchise (Exondys 51, Vyondys 53, Amondys 45). Sarepta's platform extends gene therapy into additional limb-girdle muscular dystrophies and CNS disorders.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Sarepta Corporate Presentation 2025 | Corporate overview | January 1, 2025 | 60 |